Prolonged duration of response in lenvatinib responders with thyroid cancer

Endocrine-related Cancer
Andrew G GianoukakisMahadi Baig

Abstract

We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary analysis. In this randomized, double-blind, multicenter, placebo-controlled phase 3 study, patients ≥18 years old with measurable, pathologically confirmed RR-DTC with independent radiologic confirmation of disease progression within the previous 13 months were randomized 2:1 to oral lenvatinib 24 mg/day or placebo. The main outcome measures for this analysis are DOR and progression-free survival (PFS). The median DOR for all lenvatinib responders (patients with complete or partial responses; objective response rate: 60.2%; 95% confidence interval (CI) 54.2-66.1) was 30.0 months (95% CI 18.4-36.7) and was generally similar across subgroups. DOR was shorter in patients with greater disease burden and with brain and liver metastases. Updated median PFS was longer in the overall lenvatinib group vs placebo (19.4 vs 3.7 months; hazard ratio (HR) 0.24; 99% CI 0.17-0.35; nominal P < 0.0001). In lenvatinib responders, median PFS was 33.1 months (95% CI 27.8-44.6) vs 7.9 months (95% CI 5.8-10.7) in non-responders. The median DOR of 30.0 months seen with patien...Continue Reading

References

Nov 27, 2004·Endocrinology·Rosanne St BernardShereen Ezzat
Oct 29, 2009·Thyroid : Official Journal of the American Thyroid Association·UNKNOWN American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerR Michael Tuttle
May 15, 2013·Lancet·Mingzhao XingMartin Schlumberger
Nov 5, 2014·Therapeutic Advances in Medical Oncology·Francis Worden
Feb 12, 2015·The New England Journal of Medicine·Martin SchlumbergerSteven I Sherman
Jun 17, 2016·Current Pharmaceutical Design·Rasmus LaursenDaniela Grimm
Sep 1, 2012·Expert Review of Endocrinology & Metabolism·Furio PaciniLori Wirth

❮ Previous
Next ❯

Citations

Jul 20, 2019·Endocrine Reviews·Maria E CabanillasCamilo Jimenez
Oct 15, 2019·Expert Opinion on Drug Discovery·Rosa Maria ParagliolaSalvatore Maria Corsello
Dec 22, 2019·International Journal of Molecular Sciences·Ole Vincent AnckerDaniela Grimm
Sep 11, 2020·Thyroid : Official Journal of the American Thyroid Association·Carlotta GianiRossella Elisei
Nov 8, 2020·Cancers·Hossein TabatabaeianYvonne Tay
Feb 12, 2021·Current Treatment Options in Oncology·Kevin C Miller, Ashish V Chintakuntlawar
Feb 20, 2021·Nature Reviews. Endocrinology·Matti L GildBruce G Robinson
May 18, 2021·Critical Reviews in Oncology/hematology·Vincenzo MarottaLuciano Pezzullo
Aug 3, 2021·Frontiers in Endocrinology·Tanner FullmerMark Zafereo
Aug 25, 2021·Expert Opinion on Investigational Drugs·Silvia Martina FerrariPoupak Fallahi
Jul 25, 2021·The Journal of Clinical Endocrinology and Metabolism·Asumi IesatoCarmelo Nucera

❮ Previous
Next ❯

Software Mentioned

SELECT

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Marcia S BroseArti Hurria
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Makoto TaharaAndrew G Gianoukakis
The New England Journal of Medicine
Martin J SchlumbergerSteven I Sherman
© 2022 Meta ULC. All rights reserved